Salvatore Martini
Overview
Explore the profile of Salvatore Martini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
283
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pisaturo M, Russo A, Grimaldi P, Martini S, Coppola N
Front Cell Infect Microbiol
. 2025 Feb;
14:1382017.
PMID: 40008233
In the last few years there have been innovations in HDV therapy which have brought new excitement in the scientific community also considering the few therapeutic opportunities. Recently, new molecular...
2.
Russo A, Martini S, Pisaturo M, Palamone M, Russo M, Zollo V, et al.
Infect Chemother
. 2024 Oct;
56(3):395-405.
PMID: 39370125
Background: The aim of this meta-analysis was to synthesize the available evidence from the literature on the efficacy and safety of integrase inhibitor-based two drug regimens compared to triple drug...
3.
Corti N, Menzaghi B, Orofino G, Guastavigna M, Lagi F, Di Biagio A, et al.
Viruses
. 2024 Apr;
16(4).
PMID: 38675955
Cardiovascular disease (CVD) is common in people with HIV (PWH), and has great impact in terms of morbidity and mortality. Several intertwined mechanisms are believed to play a role in...
4.
Martini S, Ricci E, Masiello A, Zaca S, Celesia B, Ferrara S, et al.
Biomedicines
. 2024 Apr;
12(4).
PMID: 38672129
Background: Antiretroviral therapy has allowed a clear improvement in prognosis for HIV patients, but metabolic problems, such as dyslipidemia, remain. This can lead to the development of atheromatous plaques. Our...
5.
Martini S, Poli G
Front Med (Lausanne)
. 2024 Apr;
11:1402565.
PMID: 38633309
No abstract available.
6.
Maggi P, Ricci E, Martinelli C, De Socio G, Squillace N, Molteni C, et al.
Viruses
. 2023 Jul;
15(7).
PMID: 37515298
Doravirine (DOR) is a newly approved non-nucleoside reverse transcriptase inhibitor (NNRTI). We aimed to investigate, in a real-life setting, how switching to a DOR-based regimen rather than a rilpivirine (RPV)-based...
7.
Martini S, Pisaturo M, Russo A, Palamone M, Russo M, Zollo V, et al.
Pathogens
. 2023 Jul;
12(7).
PMID: 37513772
Background: Antiretroviral therapy has increasingly improved management of HIV infection, ensuring long-term efficacy and tolerability. Each class of antiretrovirals has, however, different characteristics and different tolerability profiles. The literature data...
8.
Russo A, Pisaturo M, Zollo V, Martini S, Maggi P, Numis F, et al.
J Clin Med
. 2023 Jun;
12(12).
PMID: 37373748
Background And Aim: The nature of the association between obesity and poor prognosis of COVID-19 without the evaluation of other co-pathologies associated has not yet been clearly evaluated. The aim...
9.
Martini S, Maggi P, Gervasoni C, Onorato L, Ferrara S, Alessio L, et al.
Biomedicines
. 2022 Dec;
10(12).
PMID: 36551920
Background: The introduction of tenofovir alafenamide (TAF) in antiretroviral therapy has deeply modified the choice of the backbone for different treatment regimens, allowing the prevention of the bone and renal...
10.
Scotto R, Buonomo A, De Pascalis S, Nerilli M, Pinchera B, Staiano L, et al.
Expert Rev Gastroenterol Hepatol
. 2021 Feb;
15(9):1057-1063.
PMID: 33573411
Background: Second generation direct acting antivirals (DAAs) drastically changed the landscape of chronic HCV (CHCV). Aim of this paper was to assess the effectiveness of DAAs, also looking at the...